

RELISH PHARMACEUTICALS LIMITED

Regd. Office: 1-2 MOON LIGHT 3RD FLOOROPP:GURUKUL DRIVE-IN-ROAD, MEMNAGAR, AHMEDABAD-380052

Email Id: info@relishpharma.com Phone : 079-66522247 CIN: L24231GJ1993PLC019079

PART I							
Statement of Standalone Unaudited Results for the Quarter Ended 30/09/2015							(In lacs)
Particulars	3 Months Ended (30-09-2015)	3 Months Ended (30-06-2015)	3 Months Ended (30-09-2014)	6 Months Ended (30-09-2015)	6 Months Ended (30-09-2014)	Year to date figures for current period ended (31/03/2015)	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
<b>1 Income from operations</b>							
(a) Net sales/income from operations (Net of excise duty)	92.24	30.01	109.43	122.33	184.89	263.78	
(b) Other operating income	50.00	50.00	5.23	100.00	42.29	0.00	
<b>Total income from operations (net)</b>	<b>142.24</b>	<b>80.01</b>	<b>109.43</b>	<b>222.33</b>	<b>227.18</b>	<b>263.78</b>	
<b>2 Expenses</b>							
(a) Cost of materials consumed	20.46	47.66	26.21	68.12	85.04	139.86	
(b) Purchase of stock-in-trade	0.00		0.00	0.00	0.00	0.00	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	66.05	-32.92	7.87	2.13	-1.93	(18.37)	
(d) Employee benefits expense	27.35	28.92	33.05	56.48	56.67	108.08	
(e) Depreciation and amortisation expense	15.00	15.00	16.00	30.00	32.00	60.00	
(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	4.67	7.25	21.40	12.04	46.37	43.65	
<b>Total expenses</b>	<b>133.53</b>	<b>65.91</b>	<b>104.53</b>	<b>168.77</b>	<b>218.15</b>	<b>333.22</b>	
<b>3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>8.71</b>	<b>14.10</b>	<b>4.90</b>	<b>53.56</b>	<b>9.03</b>	<b>(69.44)</b>	
4 Other income	0.38	0.44	0.00	0.82	0.00	64.58	
<b>5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>9.09</b>	<b>14.54</b>	<b>4.90</b>	<b>54.38</b>	<b>9.03</b>	<b>(4.86)</b>	
6 Finance costs	0.00		0.00	0.00	0.00	0.13	
<b>7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)</b>	<b>9.09</b>	<b>14.54</b>	<b>4.90</b>	<b>54.38</b>	<b>9.03</b>	<b>(4.99)</b>	
8 Exceptional items	0.00		0.00	0.00	0.00	30.85	
<b>9 Profit / (Loss) from ordinary activities before tax (7 + 8)</b>	<b>9.09</b>	<b>14.54</b>	<b>4.90</b>	<b>54.38</b>	<b>9.03</b>	<b>25.86</b>	
10 Tax expense - Provision for taxation	0.00		0.00	0.00	0.00	13.62	
<b>11 Net Profit / (Loss) from ordinary activities after tax (9 + 10)</b>	<b>9.09</b>	<b>14.54</b>	<b>4.90</b>	<b>54.38</b>	<b>9.03</b>	<b>12.24</b>	
12 Extraordinary items	0.00		0.00	0.00	0.00	0.00	
<b>13 Net Profit / (Loss) for the period (11 + 12)</b>	<b>9.09</b>	<b>14.54</b>	<b>4.90</b>	<b>54.38</b>	<b>9.03</b>	<b>12.24</b>	
14 Share of profit / (loss) of associates*	0.00		0.00	0.00	0.00	0.00	
15 Minority interest *	0.00		0.00	0.00	0.00	0.00	
<b>16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *</b>	<b>9.09</b>	<b>14.54</b>	<b>4.90</b>	<b>54.38</b>	<b>9.03</b>	<b>12.24</b>	
17 Paid-up equity share capital (Face Value of the Share shall be indicated)	156.57	156.57	156.57	156.57	156.57	156.57	
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	0.00	
19.i Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):							
(a) Basic	0.06	0.09	0.03	0.35	0.06	0.08	
(b) Diluted	0.06	0.09	0.03	0.35	0.06	0.08	
19.ii Earnings per share (after extraordinary items) (of Rs. 10/- each) (not annualised):							
(a) Basic	0.06	0.09	0.03	0.35	0.06	0.08	
(b) Diluted	0.06	0.09	0.03	0.35	0.06	0.08	

Notes: 1. The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 7th November 2015

2. The Company has only single Reportable Business Segment in terms of requirements of Accounting Standard 17.


3. Previous quarter's figures have been re-grouped / re-arranged wherever necessary.

4. During the quarter ended 30th September, 2015, 0 complaint was received and attended.

Place : Ahmedabad

Date : 07/11/2015

For Relish Pharmaceuticals Limited




JAY J. MEHTA

Director

DIN: 02145467

PART II		Quarter Ended 30/09/2015						Year to date figures for current period ended (31/03/2015)
		3 Months Ended (30-09-2015)	3 Months Ended (30-06-2015)	3 Months Ended (30-09-2014)	6 Months Ended (30-09-2015)	6 Months Ended (30-09-2014)		
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>							
<b>1</b>	Public shareholding							
	- Number of shares	795905	795905	795905	795905	795905	795905	
	- Percentage of shareholding	50.83%	50.83%	50.83%	50.83%	50.83%	50.83%	
<b>2</b>	Promoters and Promoter Group Shareholding **							
	a) Pledged/Encumbered							
	- Number of shares	0.00	0.00	0.00	0.00	0.00	0.00	
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
	- Percentage of shares (as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
	b) Non-encumbered							
	- Number of shares	769770	769770	769770	769770	769770	769770	
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
	- Percentage of shares (as a % of the total share capital of the company)	49.17%	49.17%	49.17%	49.17%	49.17%	49.17%	
<b>B</b>	<b>INVESTOR COMPLAINTS</b>							
	Pending at the beginning of the quarter							
	Received during the quarter	0	0	0	0	0	0	
	Disposed of during the quarter	0	0	0	0	0	0	
	Remaining unresolved at the end of the quarter	0	0	0	0	0	0	



**RELISH PHARMACEUTICALS LIMITED**

Regd. Office: 1-2 MOON LIGHT 3RD FLOOR OPP: GURUKUL DRIVE-IN-ROAD, MEMNAGAR, AHMEDABAD-380052

Email Id: info@relishpharma.com Phone : 079-66522247 CIN: L24231GJ1993PLC019079

**2. Annexure-IX of Clause 41**

STATEMENT OF ASSETS AND LIABILITIES		STANDALONE	
		As at current period ended 30-09-2015	As at current year end 31-3-2015
		(Unaudited)	(Audited)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>1 SHAREHOLDERS FUNDS</b>		
	(a) Share Capital	156.57	156.57
	(b) Reserves and surplus	1262.25	1238
	(c) Money received against share warrant		
	<b>SHAREHOLDERS FUNDS</b>	1418.82	1394.57
	<b>2 SHARE APPLICATION MONEY PENDING ALLOTMENT</b>		
	<b>3 NON - CURRENT LIABILITIES</b>		
	(a) Long-term borrowing	0	116.02
	(b) Deferred tax liabilities (net)	228.65	229.22
	(c) Other long-term liabilities		0
	(d) long-term provisions		0
	<b>NON - CURRENT LIABILITIES</b>	228.7	345.2
	<b>4 CURRENT LIABILITIES</b>		
	(a) Short-term borrowing	0	38.08
	(b) Trade payables	20.98	42.15
	(c) Other current liabilities	3.6	0
	(d) Short-term provision	6.89	7.47
	<b>CURRENT LIABILITIES</b>	31.47	87.7
	<b>TOTAL EQUITY AND LIABILITIES</b>	1678.94	1827.5
<b>B</b>	<b>ASSETS</b>		
	<b>1 NON - CURRENT ASSETS</b>		
	(a) Fixed assets	1146.24	1140.49
	(b) Non-current investments	3.41	3.36
	(c) Deferred tax assets (net)		0
	(d) long-term loans and advances	6.15	0
	(e) Other non-current assets		6.56
	<b>NON - CURRENT ASSETS</b>	1155.80	1150.41
	<b>2 CURRENT ASSETS</b>		
	(a) Current investments	0.11	0.11
	(b) Inventories	101.76	132.12
	(c) Trade receivables	133.14	47.65
	(d) Cash and cash equivalents	54.46	49.25
	(e) Short-term loans and advances	176.62	385.07
	(f) Other current assets	57.05	62.9
	<b>CURRENT ASSETS</b>	523.14	677.1
	<b>TOTAL ASSETS</b>	1678.94	1827.5

